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Abstract
Backgrounds: Zero-events studies frequently occur in systematic reviews of adverse events, which consist of an
important source of evidence. We aimed to examine how evidence of zero-events studies was utilized in the meta-
analyses of systematic reviews of adverse events.
Methods: We conducted a survey of systematic reviews published in two periods: January 1, 2015, to January 1,
2020, and January 1, 2008, to April 25, 2011. Databases were searched for systematic reviews that conducted at
least one meta-analysis of any healthcare intervention and used adverse events as the exclusive outcome. An
adverse event was defined as any untoward medical occurrence in a patient or subject in healthcare practice. We
summarized the frequency of occurrence of zero-events studies in eligible systematic reviews and how these
studies were dealt with in the meta-analyses of these systematic reviews.
Results: We included 640 eligible systematic reviews. There were 406 (63.45%) systematic reviews involving zero-
events studies in their meta-analyses, among which 389 (95.11%) involved single-arm-zero-events studies and 223
(54.93%) involved double-arm-zero-events studies. The majority (98.71%) of these systematic reviews incorporated
single-arm-zero-events studies into the meta-analyses. On the other hand, the majority (76.23%) of them excluded
double-arm-zero-events studies from the meta-analyses, of which the majority (87.06%) did not discuss the
potential impact of excluding such studies. Systematic reviews published at present (2015-2020) tended to
incorporate zero-events studies in meta-analyses than those published in the past (2008-2011), but the difference
was not significant (proportion difference=−0.09, 95% CI −0.21 to 0.03, p = 0.12).
Conclusion: Systematic review authors routinely treated studies with zero-events in both arms as “non-informative”
carriers and excluded them from their reviews. Whether studies with no events are “informative” or not largely
depends on the methods and assumptions applied, thus sensitivity analyses using different methods should be
considered in future meta-analyses.
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Background
In an era of evidence-based medicine, systematic reviews
and meta-analyses represent the most important source
of evidence and have been widely used to assess the ef-
fectiveness and safety of healthcare interventions [1]. In
a meta-analysis, data from available studies on the same
topic are quantitatively synthesized in an effort to reduce
uncertainty and increase precision [2, 3]. Standard meta-
analysis methods are based on large-sample approxima-
tion, and it can achieve reasonable statistical properties
for assessment of efficacy. However, for assessment of
safety, due to the potential low event rate and limited
sample size, the observed events tend to be rare and
often zero, and thus the assumption may no longer hold,
further challenging data synthesis [4, 5].
Researchers generally divide studies with zero-events
as single-arm-zero-events studies and double-arm-zero-
events studies [6]. The former indicates that no events
occur in one of the comparative arms; the latter indi-
cates no events occur in both arms. For studies with
zero-events in a single arm, there are several well-
established methods (e.g., Peto odds ratio [7–9]) avail-
able to synthesize the information from such studies into
a meta-analysis, and there is a unanimous agreement
that such studies should not be excluded [5, 10]. How-
ever, for studies with zero-events in both arms, incorp-
orating these studies is controversial and complex [11].
Standard meta-analysis methods focus on the intervention
effects, but they seldom take care of the absolute risks of
the arms; the relative measurements (i.e., odds ratio, risk
ratio) and their variances are undefined for such studies
and are therefore treated as non-informative in the meta-
analysis. While an increasing body of evidence has shown
that such studies are not necessarily non-informative from
both clinical and statistical perspectives [6, 12, 13],
depending on the methods or assumptions utilized for
the synthesis (e.g., generalized linear mixed model,
beta-binomial model [6, 14–19]).
The contradictory views regarding studies with zero
events in both arms complicate decisions for systematic
review authors and policymakers, who ultimately de-
termine healthcare practice [20, 21]. The preference
on dealing with such studies may influence future
systematic review authors. It is, therefore, necessary
and essential to keep abreast of how current meta-
analyses deal with studies with zero events and make
timely recommendations to promote the appropriate
future practice. In this study, we conducted a survey
of systematic reviews of adverse events to explore the
frequency of occurrence of zero-events studies and
how such studies were dealt with in the meta-
analyses of these systematic reviews. We further dis-




An a priori protocol for this study was developed to formu-
late its design and conduct. Any protocol deviations were
recorded (Additional file: Protocol). The current study is re-
ported according to the PRIO-harms checklist [22].
Data source
We searched PubMed for all relevant systematic reviews
with adverse events as the exclusive outcome from Janu-
ary 1, 2015, to January 1, 2020. Although the limitation
on the time range is somewhat arbitrary, we believe it
would be representative of the current methods
employed by meta-analysts to deal with zero-events
studies. The primary search strategy was developed by a
librarian and then discussed with the lead author (a
methodologist) for further improvement. The complete
search strategy is presented in the Additional file. In
order to understand the potential changes in the prefer-
ence of the methods for zero-events studies, we used a
previous dataset that was collected in 2011, which in-
cluded published systematic reviews of adverse events
from January 1, 2008 to April 25, 2011. The details were
documented in our published article [20].
Inclusion criteria
We considered all systematic reviews that conducted at
least one meta-analysis of any healthcare intervention
and used safety as the exclusive outcome, regardless of
whether the included studies were randomized con-
trolled trials (RCT) or non-randomized studies of inter-
vention (NRSI) or both. We defined adverse events as
“any untoward medical occurrence in a patient or sub-
ject in clinical practice” [23], which could be an adverse
effect, adverse reaction, harm, or complication associated
with any healthcare intervention [24]. All studies of the
meta-analyses were restricted to have binary outcomes.
We did not consider meta-analyses assessing both effect-
iveness and safety; we also did not consider those syn-
thesizing incidence or prevalence of adverse events that
only had a single arm. Systematic reviews that were
combined with publication of an original study and sys-
tematic reviews without meta-analysis were not consid-
ered [25]. In addition, the gray literature was not
considered as we only focused on published meta-
analyses. We did not consider the reference lists of in-
cluded systematic reviews by hand search.
Two authors (XZ, CX) screened the literature searches
separately through the online application Rayyan. We
first screened the titles and abstracts to exclude those re-
cords obviously out of our scope (e.g., narrative review,
meta-analysis of effectiveness). Full-text was obtained for
included titles and abstracts or those that had disagree-
ment to make a final decision. Any disagreements were
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discussed by the two authors until a final consensus was
reached [26].
Data collection
The current study focused on how zero-events studies
were dealt with in meta-analyses of the included system-
atic reviews. The following baseline information was ex-
tracted (by Access 2016, Microsoft, USA): author name,
year of publication, region of the corresponding author,
type of meta-analysis employed, study type for meta-
analysis, protocol registration, effect estimator (e.g., odds
ratio, OR; risk ratio, RR; and risk difference, RD), and
funding information. We were particularly interested in
information about how zero-studies were handled. Spe-
cifically, we considered the following questions for each
selected systematic review:
1) In the systematic review, did any meta-analysis con-
tain zero-events studies?
2) If zero-events studies were involved, what were the
types of zero-events studies (e.g., no event in a sin-
gle arm, double arms, or both)?
3) If zero-events studies were involved, whether the
authors specified methods to deal with zero-events
studies?
4) If the authors specified methods, whether they
clarified reasons for selecting the chosen method
for handling zero-events studies?
5) If zero-events studies were involved, how were they
dealt with by the authors?
6) Whether a sensitivity analysis was employed
through at least one different synthesis method for
dealing with zero-events studies?
7) For those that failed to synthesize studies with
zero-events, did the authors discuss the potential
impact of excluding such studies on the results?
The baseline information was extracted by one author
(XZ) and then double-checked by another author (KJ).
The information about how the meta-analyses dealt with
zero-events studies was collected by one methodologist
(CX) in this area and verified by two other statisticians
(LFK, LL). It should be noted that for each included sys-
tematic review, two or more meta-analyses were likely to
be involved. We only counted each systematic review
once in terms of whether zero-events studies were in-
cluded and how these studies were handled, because the
pooling method was consistent across meta-analyses
within the same systematic review. The judgment of
whether a meta-analysis contained zero-events studies
was based on the forest plot, baseline table, and/or text
that indicated that studies with no events were excluded.
For network meta-analyses, we only considered pairwise
comparisons, if applicable.
Data analysis
The baseline information was summarized in terms of
frequencies and proportions. Our primary outcomes of
interest were how meta-analyses with zero-events were
dealt with; we classified them by zero-events types (i.e.,
single-arm-zero-events, double-arm-zero-events). Other
relevant information was also summarized in terms of
frequencies and proportions with an exact 95% confi-
dence interval (CI). The exact method has been proven
to be a valid solution for calculating proportions even
when zero-events occur [27].
We further compared the proportions of studies ex-
cluding studies with zero-events in a single arm and in
both arms for the two datasets (2015–2020 vs. 2008–
2011) as planned in the protocol. The proportions were
also compared in terms of whether an a priori protocol
for handling zero events was developed or not. The pro-
portion difference (PD) was used to measure the
difference as a valid method for measuring the effect
even in the presence of zero counts [26, 28]. Fisher’s
exact test was used for sensitivity analysis when events
were rare (i.e., less than 5). We did not use a continuity
correction or Peto’s OR since the sample sizes in com-
parative groups were generally unbalanced, and these
two methods could lead to large bias [6, 29]. Given the
potentially high proportions of meta-analyses that ex-
cluded studies with zero events, we expected no PD in-
volving double zero counts in this study.
All statistical analyses were performed by Stata (ver-
sion 14.0/SE, Stata, College Station, TX) and MetaXL
(version 5.3, EpiGear, Australia). The significance level
was pre-specified as alpha = 0.05.
Results
Basic characteristics
In the dataset collected in 2011, we identified 309 poten-
tially relevant systematic reviews, of which 17 were miss-
ing, leaving 292 with full texts for assessment. We
further excluded those that did not conduct meta-
analyses, had all outcomes as continuous variables, con-
tained original research, or only investigated the inci-
dence of adverse events. We included 184 systematic
reviews for analysis (Fig. 1). In the dataset collected cur-
rently, we identified 511 eligible systematic reviews; all
conducted meta-analyses. After excluding 55 reviews
that only investigated the incidence of adverse events,
we obtained 456 systematic reviews for analysis (Fig. 1).
Among the 640 systematic reviews in total, 483
(75.47%) focused on drug interventions, 108 (16.88%) on
surgery or devices, and 49 (7.66%) on other interven-
tions. These proportions were similar for the two data-
sets analyzed separately (Fig. 1). Most (n = 585, 91.41%)
of these systematic reviews employed pairwise compari-
sons in the meta-analyses. Only four used individual
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participant data. Protocols were reported by 166
(25.94%) of the systematic reviews, and the majority (n =
474, 74.06%) failed to refer to any information on proto-
col development. Most systematic reviews used evidence
from RCTs (n = 460, 71.88%) for their meta-analyses; 89
(13.91%) used evidence from NRSIs. The most widely
used effect estimators were the OR and RR; the propor-
tions were 41.56% and 49.38%, respectively. The RD was
seldom used to measure the effect (n = 15, 2.34%)
(Table 1).
For the 640 systematic reviews, 146 (n = 146, 22.80%)
did not provide sufficient information on whether zero-
events studies were involved, and 406 (63.45%) system-
atic reviews encountered zero-events studies in their
meta-analyses. Among these 406 reviews, 90 were identi-
fied from the first dataset, and 316 were from the second
dataset. There was a significantly higher proportion of
zero-events studies in systematic reviews published from
2015 to 2020 than those published from 2008 to 2011
(67.11% vs. 48.91%, p < 0.001). For the 406 systematic re-
views with zero-events studies in their meta-analyses,
174 (42.86%) involved single-arm-zero-events studies
only, 7 (1.72%) involved double-arm-zero-events studies
only, and 208 (51.23%) involved both single- and
double-zero-events studies. Only 131 (32.27%) system-
atic reviews reported methods to deal with zero-events
studies in meta-analyses. Among these 131 systematic
reviews, only 44 (33.59%) provided reason(s) for select-
ing relevant methods to deal with zero-events studies
(Table 2).
Dealing with zero-events studies in meta-analysis: in the
past
In the 90 systematic reviews involving zero-events stud-
ies in meta-analyses in 2008–2011, 84 involved single-
arm-zero-events studies, and 54 involved double-arm-
zero-events studies. Figure 2 presents the methods used
to deal with zero-events studies.
Among the 84 systematic reviews with single-arm-
zero-events studies, 83 incorporated evidence of these
studies in meta-analyses, and 1 (1.19%) excluded these
studies from meta-analyses. The most commonly used
method for dealing with single-arm-zero-events studies
was the continuity correction or its variants (e.g., empir-
ical correction, opposite-arm correction [29]) (n = 72),
followed by Peto’s OR (n = 6, 7.14%). Other methods,
such as the generalized linear mixed model (n = 1,
1.19%) and Mantel-Haenszel RD (n = 2, 2.38%), were
seldom used. For 1 review, we could not judge which
method they employed. We also identified two (2.38%)
systematic reviews that used the “collapsed table” (also
refers to “treat-as-one-trial”) method for the pooling;
however, without weighting, this method could be mis-
leading due to Simpson’s paradox (i.e., a trend that ap-
pears in individual studies but disappears or reverses
after unweighted incorporation) [30].
For 54 systematic reviews with double-arm-zero-
events studies, the most commonly used procedure was
excluding these studies (n = 45, 83.33%) from the meta-
analyses. Importantly, 40 (88.89%) of these 45 systematic
reviews did not discuss any potential impact of
Fig. 1 The literature screen process
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excluding such studies on the results. The remaining 9
systematic reviews used the continuity correction or its
variants (n = 4, 7.4%), Mantel-Haenszel RD (n = 2,
3.70%), “collapsed table” (n = 2, 3.70%), or generalized
linear mixed model (n = 1, 1.85%) to synthesize evidence
from these studies in meta-analyses (Fig. 2).
Dealing with zero-events studies in meta-analysis: at
present
In the 316 systematic reviews involving zero-events stud-
ies in meta-analyses in 2015–2020, 305 involved single-
arm-zero-events studies, and 169 involved double-arm-
zero-events studies.
Among the 305 systematic reviews with single-arm-
zero-events studies in meta-analyses, the most com-
monly used method for dealing with single-arm-zero-
events studies remained continuity correction or its vari-
ants (n = 263, 86.23%), followed by Peto’s OR (n = 23,
7.54%), and then the Mantel-Haenszel RD (n = 11,
3.61%). Other methods, such as the “collapsed table” (n
= 2, 0.66%), stratified conditional logistic regression (n =
1, 0.33%), using non-adverse events as outcomes (n = 1,
0.33%), were seldom used. Again, for 1 (0.33%) system-
atic review, we could not judge which method they
employed. It should be highlighted that two (0.66%) sys-
tematic reviews excluded such studies from their meta-
analyses.
For 169 systematic reviews with double-arm-zero-
events studies, the most commonly used procedure was
excluding these studies (n = 125, 73.96%) from the
meta-analyses. Again, in these 125 systematic reviews,
108 (86.40%) failed to discuss the potential impact of ex-
cluding zero-events studies on the results. There were
41 systematic reviews that used the continuity correction
or its variants (n = 27, 15.98%), Mantel-Haenszel RD (n
= 9, 5.33%), “collapsed table” (n = 2, 1.18%), Peto’s OR
with 0.5 correction (n = 2, 1.18%), and beta-binomial
model (n = 1, 0.59%) to synthesize evidence of such
studies in meta-analyses (Fig. 2). However, for 3 (1.78%)
reviews, we could not judge which method they
employed.
Comparing the present to the past
Compared to the past, there were more systematic re-
views incorporating evidence from double-arm-zero-
events studies into meta-analyses rather than excluding
them. This change was primarily attributable to the in-
creased use of the continuity correction (or its variants)
method and Mantel-Haenszel RD (Fig. 2). We further
quantitatively compared the proportions of excluding
zero-events studies for these two time periods (2015–
2020 vs. 2008–2011); see Additional file: Fig.S1. Our re-
sults suggested that although recent systematic reviews
tended to incorporate zero-events studies in meta-
Table 1 Basic characteristics of included systematic reviews on
adverse events
Basic characteristics No. of systematic




Region of corresponding author
Africa 15 (2.34%)






Surgery or device 108 (16.88%)
Others (e.g., complementary medicine) 49 (7.66%)
Type of meta-analysis
Pairwise meta-analysis 585 (91.41%)
Network meta-analysis 17 (2.66%)
Both pairwise and network meta-analyses 32 (5.0%)
Association 2 (0.31%)




Type of study for meta-analysis
Randomized controlled trial (RCT) 460 (71.88%)
Non-randomized study of intervention (NRSI) 89 (13.91%)
Both RCT and NRSI 87 (13.59%)
Not reported 4 (0.63%)
Effect estimator
Odds ratio, including Peto’s OR 266 (41.56%)
Risk ratio or relative risk 316 (49.38%)
Hazard ratio 9 (1.41%)
Risk difference 15 (2.34%)
Others (e.g., mixed use, Chi2, coef.) 34 (5.31%)
Systematic review with zero-events studies in meta-analysis
Yes 406 (63.45%)
No 88 (13.75%)
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analyses, the difference was not significant from either
the practical or statistical perspective (for single-arm-
zero-events: PD=−0.01, 95% CI −0.03, 0.02, p = 0.67; for
double-arm-zero-events: PD=−0.09, 95% CI −0.21, 0.03,
p = 0.12). Sensitivity analysis was employed by Fisher’s
exact test, which showed consistent results (p = 0.52).
Additional analysis
The proportions of excluding zero-events studies were
also compared in terms of whether a protocol was re-
ported in those systematic reviews (Additional file:
Fig.S2). Our results suggested no substantial difference
(for single-arm-zero-events: PD=−0.00, 95% CI −0.02,
0.01, p = 0.64; for double-arm-zero-events: PD=−0.07,
95% CI −0.19, 0.06, p = 0.29) in the proportions of ex-
cluding for those with and without a protocol. Sensitivity
analysis was employed by Fisher’s exact test, which
showed consistent results (p = 1.00).
Discussion
Main findings
In this study, we conducted a large-scale survey on sys-
tematic reviews with meta-analyses of adverse events as-
sociated with various healthcare interventions to
examine how they dealt with zero-events studies. Our
results suggested that in the majority (76.23%) of the
systematic reviews, studies with zero events in both arms
were excluded from meta-analyses. This was more
common in systematic reviews published earlier
(83.33%). Although an increasing proportion of system-
atic reviews attempted to synthesize evidence from stud-
ies with zero events in both arms in recent years, the
majority still excluded such studies (73.95%).
Implications
In our study, we noticed that among the majority of sys-
tematic reviews that excluded zero-events studies, only a
small proportion (12.94%, Table 2) discussed the poten-
tial impact of excluding zero-events studies in both arms
on their results. Although there is still controversy
among statisticians for whether studies with zero-events
in both arms should be synthesized in a meta-analysis, it
is not doubtful that systematic review authors should in-
form and discuss the results of such studies [20]. Clinical
trials might tend to under-report adverse events in the
publications [31, 32], so that the zero-events may be
caused by the selective reporting. This practice is dan-
gerous because such selective reporting may lead to a
large amount of bias for the meta-results. From this
point, simply treating studies with zero-events studies as
“non-informative” may be unreasonable because this
leads to neglecting such studies by systematic review
authors.
The controversy of dealing with studies with zero
events in both arms is mainly due to the methods used
and assumptions of the absolute risks. As we mentioned
Fig. 2 Methods for dealing with zero-events studies in eligible systematic reviews
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earlier, the standard methods make no assumptions on
the absolute risks of the arms; when there are no events
in both arms, the relative measures cannot be defined.
Böhning and Sangnawakij recently compared the likeli-
hood of excluding (based on a conditional binomial
model) and including (based on a Poisson regression
model) studies with zero-events in both arms by math-
ematical derivations; they found that such studies do not
contribute to the likelihood [19], supporting the exclu-
sion of studies with no events. However, this may not be
the case under some other models (e.g., multilevel logis-
tic regression model [14], beta-binomial [18]), where the
relative measure could be defined based on certain as-
sumptions. Many approaches have been proposed to in-
clude studies with no events and compare the
corresponding results with those excluding such studies
[6, 11–13, 18, 33–35]. Considering the opinions of re-
searchers on both sides, perhaps sensitivity analysis
using different methods for including and excluding
studies with no events should be considered in future
meta-analyses [29, 36].
We noticed that for those meta-analyses that synthesize
the information from studies with no events, the majority
used the continuity correction or its variants. It has been
criticized that the continuity correction and its variants
add pseudo-observations to the data set that potentially
lead to large bias in the estimates [6, 11]. Statisticians have
advocated avoiding the use of continuity correction in this
situation and provided several better solutions (e.g., beta-
binomial [18]) that do not need additional information
[6]. Unfortunately, it seems that more systematic review
authors continued to use continuity correction for studies
with no events over time (16% at present vs. 7.4% in the
past). This implies that most of the systematic review au-
thors may not be aware of the problems of continuity cor-
rection and more efforts are needed to improve the
common practice.
In our study, we did not detect a significant effect of
reporting a protocol on reducing the proportion of ex-
cluding zero-events studies. This is not surprising as our
recent research has shown that most systematic review
protocols on intervention safety did not develop a syn-
thesis plan for dealing with zero-events studies [27]. This
again indicates that systematic review authors routinely
neglect zero-events studies or may be inexperienced in
handling such analyses. We believe a well-established
protocol with a clear synthesis plan for zero-event stud-
ies would benefit the data synthesis process in systematic
reviews of adverse events.
How to make full use of zero-events studies in meta-
analysis?
There are currently several well-established methods
that are considered appropriate to synthesize studies
with no events, including the Mantel-Haenszel RD [37],
the exact p value function [38], and several one-stage
methods [6, 11, 14–19, 39]. The Mantel-Haenszel RD
has been justified for its advantage for dealing with stud-
ies with no events as RD is well-defined in such cases
and does not need any post hoc correction or prior in-
formation. Bradburn et al. found that Mantel-Haenszel
RD could achieve almost unbiased estimation, while the
limitation is that RD showed low statistical power that
makes it not the optimal choice for meta-analysis of rare
events [40]. Another problem of RD could be that, for
studies with the same duration of intervention and con-
trol arms, the duration could be canceled out when
using RR but not for RD, so RD is not invariant under
study duration variation, and one should consider the
potential impact of duration on RD [19]. However,
among the two-stage methods, perhaps RD is one of the
good choices, and in some situations (e.g., all studies are
zero-events studies) it is the only choice, considering
that OR and RR could not be defined in the majority of
the two-stage methods [41, 42].
Kuss has summarized existing methods that do not re-
quire a post hoc correction that could be considered for
the synthesis of studies with no events in both arms [6].
In the meanwhile, Böhning et al. proposed the zero-
inflated Poisson models to deal with excess zeros for
meta-analysis with zero-events [11, 19]. Systematic re-
view authors are strongly recommended to refer to these
methods for their meta-analysis when zero-events stud-
ies are involved. One problem could be that the applic-
ability of these methods differs a lot, and most of the
systematic review authors may not know which of them
are feasible for their meta-analysis. For example, when
the total event count in one of the arms or both arms is
zero in the meta-analysis, one-stage methods are no lon-
ger feasible. A recent framework for meta-analysis with
zero-events studies proposed by our group could be con-
sidered to help systematic review authors appropriately
make use of zero-events in meta-analysis [21]. Based on
the total event count within the meta-analysis and zero-
events type of individual studies, we can classify meta-
analyses with zero-events studies into six subtypes (see
Additional file: Fig.S3 for details). For each subtype of
meta-analysis, the applicability of available methods
could be well distinguished. They are listed under the
diagram of the framework (Additional file: Fig.S4), and
systematic review authors can easily identify one or
more appropriate methods for their meta-analysis [21].
Some further recommendations can be considered in
practice as an effort to make full use of zero-events stud-
ies in meta-analysis.
 First, standard meta-analysis methods, say, the
inverse-variance method with continuity correction,
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are not recommended as the primary choice for
meta-analysis with zero-events studies [5, 6, 29].
 Second, in case that the total event count of each
arm of a meta-analysis is at least 10, the one-stage
methods, e.g., the mixed Poisson regression models,
the beta-binomial model, the generalized linear
mixed models, and the generalized estimating equa-
tions, could be considered as the primary option [5,
6, 11, 16, 18, 19, 21, 43].
 Third, when the total event count of a meta-analysis
is < 10 or one-stage methods cannot achieve conver-
gence, two-stage methods such as Peto’s OR, Mantel-
Haenszel OR, and Mantel-Haenszel RD could be con-
sidered, while Peto’s OR and Mantel-Haenszel OR
can only be considered when there are no studies with
no events in both arms [6, 26, 38, 44].
Strengths and limitations
To the best of our knowledge, this is the first study that
investigated the methods used in published systematic
reviews for dealing with zero-events studies. Our find-
ings provided a clear picture of the preference of system-
atic review authors to exclude data when dealing with
zero-events studies in the past and at present. We pro-
vided practical recommendations to help systematic re-
view authors appropriately make use of zero-events
studies in meta-analysis. These findings will have impli-
cations for methodology guidelines, evidence-based
practice, and healthcare policy.
Several important limitations need to be highlighted.
First, the information of whether a systematic review in-
volved zero-events studies in its meta-analysis relied on
the results reported by the systematic review. We identi-
fied that 23% of systematic reviews failed to report the
case counts and sample sizes of the individual studies in
meta-analyses, making it difficult to determine if they
contained zero-events studies. One could consider this a
type of missing data (missing not at random [44, 45])
and therefore advocate caution about the potential bias
(on the estimation of the proportions of excluding zero-
events studies) caused by these missing data. Second, the
information of how zero-events studies were dealt with
was collected by a methodologist and verified by two
statisticians; however, we were unable to judge how
zero-events studies were dealt with in 5 systematic re-
views. In addition, although we repeated the analyses for
zero-events studies for each systematic review, there
were 12 systematic reviews in which we could not repeat
the results according to the methods claimed in the re-
views. They may also introduce some bias in the esti-
mated proportions. Despite these potential issues, we
believe they did not change the fact that zero-events
studies were excluded by most systematic review
authors.
Conclusions
Based on our findings, the majority of systematic review
authors excluded studies with zero events in both arms
from meta-analyses and treated them as “non-inform-
ative.” This preference was popular in systematic reviews
published 10 years ago and remains popular at present.
Whether studies with no events are “informative” or not
largely depends on the methods and assumptions ap-
plied; thus, sensitivity analyses using different methods
should be considered in future meta-analyses.
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